Dietary patterns and prostatic diseases

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 1, 2012, Pages 195-204

  Sebastiano, Cimino ^a   Vincenzo, Favilla ^a   Tommaso, Castelli ^a   Giuseppe, Sortino ^a   Marco, Russo ^a   Ivana, Caldarella ^a   Giorgio, Russo ^a   Massimo, Madonia ^b   Giuseppe, Morgia ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

Benign prostatic hyperplasia; Dietary supplements; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN RECEPTOR; BETA CAROTENE; CASPASE 6; CASPASE 9; CATECHIN; CYCLOOXYGENASE 2 INHIBITOR; EPIGALLOCATECHIN GALLATE; GENISTEIN; LYCOPENE; POLYPHENOL DERIVATIVE; POLYUNSATURATED FATTY ACID; PROSTATE SPECIFIC ANTIGEN; REACTIVE OXYGEN METABOLITE; RETINOL PALMITATE; SELENIUM; CAROTENOID; PHYTOESTROGEN;

AGE DISTRIBUTION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY MASS; BODY WEIGHT; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DNA DAMAGE; DNA SYNTHESIS; FEEDING BEHAVIOR; FRUIT; GENOMIC INSTABILITY; HUMAN; LOW CALORY DIET; LOW DRUG DOSE; LOW FAT DIET; LOWER URINARY TRACT SYMPTOM; MACROMOLECULE; NONHUMAN; ORCHIECTOMY; OXIDATIVE STRESS; PRENYLATION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL SIGNIFICANCE; TEA; VEGETABLE; WAIST HIP RATIO; WEIGHT CONTROL; DIET; FAT INTAKE; MALE; PROSTATE DISEASE; REVIEW;

CAROTENOIDS; DIET; DIETARY FATS; HUMANS; MALE; PHYTOESTROGENS; PROSTATIC DISEASES; SELENIUM; TEA; VITAMIN E;

EID: 84860858288     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e369     Document Type: Article

References (91)

1. P Boyle, R McGinn, P Maisonneuve, C La Vecchia. Epidemiology of Benign Prostatic Hyperplasia: present knowledge and studies needed. Eur Urol 20, 3-10 (1991)
2. L Denis, MS Morton, K Griffiths: Diet and its preventive role in prostatic disease. Eur Urol 35, 377-87 (1999)
3. DF Penson, PC Albertsen: Lessons learnt about early prostate cancer from large scale databases: populationbased pearls of wisdom. Surg Oncol 11, 3-11 (2002)
4. GJ Kelloff, JA Crowell, VE Steele, RA Lubet, AW Malone, CW Boone, L Kopelovich, ET Hawk, R Lieberman, JA Lawrence, I Ali, JL Viner, CC Sigman: Progress in Cancer Chemoprevention: Development of Diet-Derived Chemopreventive Agents. J Nutr 130, 467S-471S (2000)
5. KA Steinmetz, JD Potter: Vegetables, fruit and cancer: II Mechanism. Cancer Causes Control 2, 427-442 (1991)
6. H Sies. Oxidative stress: oxidants and antioxidants. Exp Physiol 82, 291-295 (2000)
7. K Wertz: Lycopene effects contributing to prostate health. Nutr Cancer 61, 775-83 (2009)
8. VM Santillo, FC Lowe: Role of vitamins, minerals and supplements in the prevention and management of prostate cancer. Int Braz J Urol 32, 3-14 (2006)
9. SK Clinton: Tomatoes or lycopene: a role in prostate carcinogenesis? J Nutr 135, S2057-9 (2005)
10. J Limpens, FH Schroeder, CM de Ridder, CA Bolder, MF Wildhagen, UC Obermueller-Jevic, K Kramer, WM van Weerden: Combined lycopene and vitamin E treatment suppress the growth of PC-346C human prostate cancer cells in nude mice. J Nutr 136, 1287-93 (2006)
11. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ: Lower prostate cancer risk in men with elevated plasm lycopene levels: results of a prospective analysis. Cancer Res 59, 1225-1230 (1999)
12. L Jian, ZJ Shen, AH Lee, CW Binns: Moderate physical activity and prostate cancer risk: a case control study in China. Eur J Epidemiol 20, 155-160 (2005)
13. GA Darlington, N Kreiger, N Lightfoot, J Purdham, A Sass-Kortsak: Prostate Cancer risk and diet, recreational physical activity and cigarette smoking. Chronic Dis Can 27, 145-153 (2007)
14. E Giovannucci, Y Liu, EA Platz, MJ Stampfer, WC Willett: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121, 1571-1578 (2007)
15. U Peters, MF Leitzmann, N Chatterjee, Y Wang, D Albanes, EP Gelmann, MD Friesen, E Riboli, RB Hayes. Serum lycopene, other carotenoids and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 16, 962-968 (2007)
16. VA Kirsh, ST Mayne, U Peters, N Chatterjee, MF Leitzmann, LB Dixon, DA Urban, ED Crawford, RB Hayes: A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15, 92-98 (2006)
17. M Etminan, B Takkouche, F Caamano-Isorna: The role of tomato product and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 13, 340-345 (2004)
18. L Jian, CJ Du, AH Lee: Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer 113, 1010-1014 (2005)
19. O Kucuk, FH Sarkar, W Sakr, Z Djuric, MN Pollak, F Khachik: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10, 861 (2001)
20. FH Schroder, MJ Roobol, ER Boeve, R de Mutsert, SD Zuijdgeestvan Leeuwen, Kersten I: Randomized, double blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 48, 922 (2005)
21. MS Ansari, NP Gupta: A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 92, 375 (2003)
22. X Zhang, Q Wang, B Neil, X Chen: Effect of lycopene on androgen receptor and prostate-specific antigen velocity. Chin Med J 123 (16), 2231-6 (2010)
23. P Palozza, M Colangelo, R Simone, A Catalano, A Boninsegna, P lanza, G Moneto, FO Ranelletti: Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 31(10), 1813-21 (2010)
24. HS Kim, P Bowen, L Chen, C Duncan, L Ghosh, R Sharifi: Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer 47, 40-7 (2003)
25. UC Obermuller-Jevic, E Olano-Martin, AM Corbacho, JP Eiserich, A van der Vliet, G Valacchi, CE Cross, L Packer: Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 133, 3356-60 (2003)
26. A Herzog, U Siler, V Spitzer, N Seifert, A Denelavas, PB Hunziker, W Hunziker, R Goralczyk, K Wertz: Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 19, 272-4 (2005)
27. SA Kaplan: Lycopene: modes of action to promote prostate health. J Urol 174, 679 (2005)
28. S Schwarz, UC Obermuller-Jevic, E Hellmis, W Koch, G Jacobi, HK Biesalski: Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J of Nutrition 13, 49-53 (2007)
29. LA Calo, E Pagnin, PA Davis, M Lodde, C Mian, A Semplicini, A Pycha: Effect of doxazosin on oxidative stressrelated proteins in benign prostate hyperplasia. Urol Int 76, 36-41 (2006)
30. GE Goodman, MD Thornquist, J Balmes, MR Cullen, FL Meyskens, GS Omenn, B Valanis, JH Williams. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 96, 1743-1750 (2004)
31. TE Rohan, GR Howe, JD Burch, M Jain: Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cancer Causes Control 6, 145-154 (1995)
32. CH Hennekens, JE Buring, JE Manson, M Stampfer, B Rosner, NR Cook, C Belanger, F Lamotte, JM Gaziano, PM Ridker, W Willett, R Peto: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334, 1145-1149 (1996)
33. ML Neuhouser, MJ Barnett, AR Kristal, CB Ambrosone, IB King, M Thornquist, GG Goodman: Dietary Supplement Use and Prostate Cancer Risk in the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 18(8), 2202-2206 (2009)
34. VL Stevens, ML McCullough, WR Diver: Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 6, 643-50 (2005)
35. KA Lawson, ME Wright, AF Subar: Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99 (2007)
36. J Virtamo, P Pietinen, JK Huttunen, P Korhonen, N Malila, MJ Virtanen, D Albanes, PR Taylor, P Albert: Incidence of cancer and mortality following alphatocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290 (4), 476-85 (2003)
37. N Cook, I Le, J Manson, J Buring, C Hennekens: Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes Control 11, 617-26 (2000)
38. RL Thangapazham, AK Singh, A Sharma, J Warren, JP Gaddipati, RK Maheshwari: Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 245(1-2), 232-241 (2007)
39. N Kurahashi, S Sasazuki, M Iwasaki, M Inoue, S Tsugane: Green Tea Consumption and Prostate Cancer Risk in Japanese Men: A Prospective Study. J Nutr 133, 2417S-2424S (2003)
40. VM Adhami, N Ahmad, H Mukhtar: Molecular targets for green tea in prostate cancer prevention. J Nutr 133, 2417S-24S (2003)
41. IA Siddiqui, VM Adhami, M Saleem, H Mukhtar: Beneficial effects of tea and its polyphenols against prostate cancer. Molecular Nutrition & Food Research 50 (2), 130-143 (2006)
42. VM Adhami, A Malik, N Zaman, S Sarfaraz, IA Siddiqui, DN Syed, F Afaq, FS Pasha, M Saleem, H Mukhtar : Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both in vitro and in vivo. Clinical Cancer Research 13, 1611 (2007)
43. S Bettuzzi, M Brausi, F Rizzi, G Castagnetti, G Peracchia, A Corti: Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study. Cancer Res 66, 1234 (2006)
44. C Brossner, K Petritsch, K Fink, M Auprich, S Madersbacher, H Adlercreutz: Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urology 64(4), 707-711 (2004)
45. H Adlercreutz, W Mazur: Phyto-oestrogens and Western diseases. Ann Med 29, 95-120 (1997)
46. J Bektic, AP Berger, K Pfeil, G Dobler, G Bartsch, H Klocker: Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgendependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol 45, 245-251 (2004)
47. R Montironi, R Mazzucchelli, JR Marshall, PH Bartels: Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol 52, 793-803 (1999)
48. BA Evans, K Griffiths, MS Morton: Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147, 295-302 (1995)
49. J Geller, L Sionit, C Partido, L Li, X Tan, T Youngkin: Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. Prostate 34, 75-79 (1998)
50. JN Davis, B Singh, M Bhuiyan, FH Sarkar: Genisteininduced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32, 123-131 (1998)
51. M Pollard, W Wolter: Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 45, 101-105 (2000)
52. JR Hebert, TG Hurley, BC Olendzki, J Teas, Y Ma, JS Hampl: Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 90, 1637-1647 (1998)
53. Ganry O: Phytoestrogens and prostate cancer risk. Prev Med 41, 1-6 (2005)
54. SJ Hong, SI Kim, SM Kwon, JR Lee, BC Chung: Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonsei Med J 43(2), 236-241 (2002)
55. KJ Helzlsouer, HY Huang, AJ Alberg: Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92, 2018-2023 (2000)
56. N Karunasinghe, J Ryan, J Tuckey: DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev 13, 391-397 (2004)
57. LC Clark, GF Combs, BW Turnbull, EH Slate, DK Chalker, J Chow, LS Davis, RA Glover, GF Graham, EG Gross, A Krongrad, JL Lesher, HK Park, BB Sanders, CL Smith, JR Taylor: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Journal of the American Medical Association 276, 1957-1963 (1996)
58. AJ Duffield-Lillico, BL Dalkin, ME Reid, BW Turnbull, EH Slate, ET Jacobs, JR Marshall, LC Clark: Nutritional Prevention of Cancer Study Group: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91(7), 608-612 (2003)
59. SM Lippman, EA Klein, PJ Goodman, MS Lucia, IM Thompson, LG Ford, HL Parnes, LM Minasian, JM Gaziano, JA Hartline, JK Parsons, JD Bearden, ED Crawford, GE Goodman, J Claudio, E Winquist, ED Cook, DD Karp, P Walther, MM Lieber, AR Kristal, AK Darke, KB Arnold, PA Ganz, RM Santella, D Albanes, PR Taylor, JL Probstfield, TJ Jagpal, JJ Crowley, FL Meyskens, LH Baker, CA Coltman: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1), 39-51 (2009)
60. PH Sánchez, AS Villegas, JD Alonso, AO Andrellucchi, K Pfrimer, LS Majem: Dietary assessment methods for micronutrient intake: a systematic review on vitamins. Br J Nutr 102, S10-37 (2009)
61. H Deneo-Pellegrini, E De Stefani, A Ronco, M Mendilaharsu: Foods, nutrients and prostate cancer: a casecontrol study in Uruguay. Br J Cancer 80, 591-597 (1999)
62. OP Heinonen, D Albanes, J Virtamo, PR Taylor, JK Hattunen, AM Hartman, J Haapakoski, N Malila, M Rautalahti, S Ripatti, H Mäenpää, L Teerenhovi, L Koss, M Virolainen, BK Edwards: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90, 440-446 (1998)
63. J Watters, SJ Lnstein, J Virtamo, D Albanes: Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival. Cancer Res 69, 3833-3841 (2009)
64. ER Miller, R Pastor-Barriuso, D Dalal, RA Riemersma, LJ Appel, E Guallar: High dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142, 37-46 (2005)
65. S Wilkinson, GW Chodak: Critical review of complementary therapies for prostate cancer. J Clin Oncol 21, 2199 (2003)
66. W Demark-Wahnefried, MA Moyad: Dietary intervention in the management of prostate cancer. Curr Opin Urol 17, 168-174 (2007)
67. DJ Kim, RP Gallagher, TG Hislop, EJ Holowaty, GR Howe, M Jain, JR Mclaughlin, CZ Teh, TE Rohan: Premorbid diet in relation to survival from prostate cancer. Cancer Causes Control 11, 65-77 (2000)
68. C Rodriguez, SJ Freedland, A Deka, EJ Jacobs, ML Mccullough, AV Patel, MJ Thun, EE Calle: Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16, 63-69 (2007)
69. SJ Freedland: Obesity and prostate cancer: a growing problem. Clin Cancer Res 11, 6763-6766 (2005)
70. D Ornish, G Weidner, WR Fair, R Marlin, EB Pettengill, CJ Raisin: Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174, 1065 (2005)
71. WJ Aronson, RJ Barnard, SJ Freedland, S Henning, D Elashoff, PM Jardack, P Cohen, D Heber, N Kobayashi: Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol 183, 345-350 (2010)
72. CM López Fontana, GM Recalde Rincón, D Messina Lombino, AL Uvilla Recupero, RF Pérez Elizalde, JD López Laur: Body mass index and diet affect prostate cancer development. Actas Urol Esp 33, 741-746 (2009)
73. S Narita, N Tsuchiya, M Saito, T Inoue, T Kumazawa, T Yuasa, A Nakamura, T Habuchi: Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis. Prostate 15, 321-335 (2008)
74. S Anderson, DM Berman, EP Jenkins, DW Russell: Delection od steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 354, 159-161 (1991)
75. M Frydenberg, TM Foo, AS Jones, J Grace, WJ Hensley, J Rogers: Benign prostatic hyperplasia-video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J Urol 146, 872-876 (1991)
76. JD McConnell, R Bruskewitz, P Walsh, G Andriole, M Lieber, HL Holtgrewe: The effect of finasteride on the risk of acute urinary retention and the needfor surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338, 557-563 (1998)
77. CS Foster: Pathology of benign prostatic hyperplasia. Prostate 9, 4-14 (2000)
78. E Giovannucci, EB Rimm, CG Chute: Obesity and benign prostatic hyperplasia. Am J Epidemiol 140, 989-1002 (1994)
79. AP Chokkalingam, M Pollak, CM Filmore: Insulin-like growth factors and prostate cancer: a population-based case control study in China. Cancer Epidemiol Biomarkers Prev 10, 421-428 (2001)
80. SE Dahle, AP Chokkalingam, YT Gao: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168, 599-604 (2002)
81. AR Kristal, KB Arnold, JM Schenk: Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. J Urol 177, 1395-400 (2007)
82. RJ Troisi, ST Weiss, DR Parker: Relation of obesity and diet to sympathetic nervous system activity. Hypertension 17, 669-677 (1991)
83. N Eikelis, M Schlaich, A Aggarwal: Interactions between leptin and the human sympathetic nervous system. Hypertension 41, 1072-1079 (2003)
84. G Kramer, M Marberger: Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 16, 25-29 (2006)
85. AR Kristal1, KB Arnold, JM Schenk, ML Neuhouser, P Goodman, DF Penson, IM Thompson: Dietary Patterns, Supplement Use, and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol 67, 925-934 (2008)
86. S Suzuki, EA Platz, I Kawachi: Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 75, 689-697 (2002)
87. P Lagiou, J Wuu, A Trichopoulou: Diet and benign prostatic hyperplasia: a study in Greece. Urology 54, 284-290 (1999)
88. J Satia-Abouta, RE Patterson, RN Schiller: Energy from fat is associated with obesity in US men: results from the Prostate Cancer Prevention Trial. Prev Med 34, 493-501 (2002)
89. GG Gordon, K Altman, AL Southren: Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men. N Engl J Med 295, 793-797 (1976)
90. JF Dorgan, JT Judd, C Longcope: Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men: a controlled feeding. Am J Clin Nutr 64, 850-855 (1996)
91. L Landsberg: Feast or famine: the sympathetic nervous system response to nutrient intake. Cell Mol Neurobiol 26, 495-506 (2006)